PARIS (Reuters) – French drugmaker Valneva said on Wednesday it will conduct a trial about the use of its COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.
The trial will be conducted in the Netherlands and results are expected in the third quarter of 2022, the statement said .
The VLA2001-307 trial will be the company’s first clinical trial to provide booster data following primary vaccination with an mRNA vaccine or natural COVID-19 infection.
(Reporting by Dominique Vidalon , Editing by Tassilo Hummel)
